ID   Hs 172.T
AC   CVCL_0660
SY   Hs-172-T; Hs172T; HS172T
DR   CLO; CLO_0003860
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-7833
DR   BioSample; SAMN03471104
DR   BioSample; SAMN10988444
DR   cancercelllines; CVCL_0660
DR   Cell_Model_Passport; SIDM01616
DR   DepMap; ACH-000088
DR   GEO; GSM136248
DR   GEO; GSM887092
DR   GEO; GSM888163
DR   IARC_TP53; 30042
DR   LiGeA; CCLE_707
DR   PharmacoDB; Hs172_T_568_2019
DR   Progenetix; CVCL_0660
DR   Wikidata; Q54895427
RX   DOI=10.1101/166199;
RX   PubMed=22460905;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Problematic cell line: Misclassified. Originally thought to be a urinary bladder carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap).
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.56%; Native American=0.85%; East Asian, North=1.69%; East Asian, South=0%; South Asian=0%; European, North=67.59%; European, South=29.31% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7833; true.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
CC   Cell type: Fibroblast; CL=CL_0000057.
ST   Source(s): ATCC
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 13
ST   D5S818: 11
ST   D7S820: 8,11
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 18,21
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Undefined cell line type
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   DOI=10.1101/166199;
RA   de Weck A., Bitter H., Kauffmann A.;
RT   "Fibroblasts cell lines misclassified as cancer cell lines.";
RL   bioRxiv 2017:166199-166199(2017).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//